Literature DB >> 1674093

Mazindol in long-term treatment of narcolepsy.

B Alvarez, M Dahlitz, J Grimshaw, J D Parkes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1674093     DOI： 10.1016/0140-6736(91)92966-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Types of psychiatric treatment. Drug treatment.

Authors:  M Prendergast
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

Review 2.  Treatment Options for Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 3.  Management of Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

Review 4.  Pharmacological management of narcolepsy and cataplexy in pediatric patients.

Authors:  Michel Lecendreux
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

5.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

6.  A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Tim L Wigal; Jeffrey H Newcorn; Nelson Handal; Sharon B Wigal; Ioulietta Mulligan; Virginia Schmith; Eric Konofal
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.